Talia

Microsorum grossum rhizomes contain phenolic acids, flavonoids, and terpenoids—bioactive classes documented in the closely related species Microsorum scolopendria—that act through COX-2 inhibition, radical scavenging, and disruption of bacterial biofilm gene expression (rsbU, spa). Samoan traditional medicine employs the rhizome specifically for respiratory complaints including coughs and asthma, though no controlled clinical trials have quantified its efficacy in human populations.

Origin & History

Microsorum grossum, commonly called talia in Samoa or lauaʻe (maile-scented fern) in Hawaiʻi, is a terrestrial and epiphytic fern native to a broad Pacific range spanning Australia, Polynesia, and extending east to Pitcairn Island. It thrives in low-elevation tropical and subtropical forests, frequently colonizing tree trunks, rocky substrates, and moist forest floors at elevations below 500 m. The species has not been formally cultivated as an agricultural or horticultural crop but spreads naturally via spores and creeping rhizomes in humid Pacific Island environments.

Historical & Cultural Context

In Samoan traditional medicine, the plant locally called talia (Microsorum grossum) has been documented as a remedy for respiratory conditions, specifically coughs and asthma, with the rhizome serving as the primary medicinal part—a use pattern consistent with Pacific Island ethnobotanical traditions that frequently emphasize fern rhizomes for their concentrated secondary metabolites. The closely related lauaʻe (broadly applied to Microsorum species in Hawaiʻi) holds deep cultural significance in Hawaiian tradition as a fragrant fern associated with the forest deity and used to scent kapa cloth, lei, and ceremonial spaces, though this cultural role is aesthetic and spiritual rather than strictly medicinal. On Rapa Nui (Easter Island), M. scolopendria (Matu'a Pua'a) forms part of the indigenous pharmacopoeia for general illness treatment, reflecting the wider Polynesian tradition of utilizing Microsorum ferns as versatile healing plants. Taxonomic ambiguity among Pacific Microsorum species—particularly the longstanding confusion between M. grossum, M. scolopendria, and related taxa—has historically complicated the attribution of specific therapeutic uses to individual species in ethnobotanical literature.

Health Benefits

- **Respiratory Symptom Relief (Traditional)**: The rhizome is used in Samoan ethnomedicine to address coughs and asthma; anti-inflammatory phenolics present in related Microsorum species may reduce airway inflammation via selective COX-2 inhibition, though this has not been tested in human respiratory models.
- **Antioxidant Activity**: Closely related M. scolopendria rhizome acetone extracts (RAE) reduce reactive oxygen species by up to 87.35% against Staphylococcus epidermidis in human dermal fibroblast cells, suggesting meaningful radical-scavenging capacity attributable to pyrogallol (9.32%), isoxanthohumol (9.09%), and cirsimaritin (8.45%).
- **Anti-Inflammatory Potential**: Extracts from taxonomically related Microsorum species selectively inhibit cyclooxygenase-2 (COX-2) over COX-1, a pharmacologically favorable profile that minimizes gastric risk while suppressing prostaglandin-mediated inflammation, though M. grossum itself has not been directly assayed.
- **Antimicrobial and Antibiofilm Action**: Polyphenolic constituents including isoxanthohumol and kaempferol-class compounds inhibit bacterial biofilm formation at concentrations of 128 µg/mL in vitro by downregulating biofilm-regulatory genes, potentially supporting immune defense against skin and systemic pathogens.
- **Phenolic Acid Richness**: Phenolic acids constitute 46–57% of relative abundance in rhizome and leaf extracts of related species, with hydroxycinnamic acid conjugates such as p-coumaroyl tartaric acid (28% in leaf hydroalcoholic extract) and feruloyl tartaric acid (12.8%) contributing broad-spectrum antioxidant and cytoprotective effects.
- **Potential Skin Protective Effects**: In vitro testing in human dermal fibroblast (HDFa) cells exposed to Staphylococcus aureus and S. epidermidis showed a 64–87% reduction in intracellular ROS following treatment with related Microsorum RAE, suggesting dermal cytoprotective potential if extrapolated cautiously to M. grossum.
- **Flavonoid-Mediated Cellular Protection**: Kaempferol 3-O-glucuronide (1.41% in leaf hydroalcoholic extract of related species) and cirsimaritin are recognized inhibitors of pro-inflammatory kinase pathways; their presence in Microsorum species supports a mechanistic basis for traditional anti-inflammatory applications, pending direct study of M. grossum.

How It Works

Polyphenolic compounds identified in the closely related Microsorum scolopendria—including isoxanthohumol, cirsimaritin, and kaempferol 3-O-glucuronide—selectively inhibit cyclooxygenase-2 (COX-2) enzyme activity over COX-1, thereby reducing synthesis of pro-inflammatory prostaglandins without the full gastric liability associated with non-selective COX inhibition. Radical-scavenging constituents such as pyrogallol and hydroxycinnamic acid conjugates (p-coumaroyl tartaric acid, feruloyl tartaric acid) neutralize reactive oxygen species through hydrogen atom transfer and single-electron transfer mechanisms, as quantified by DPPH and ORAC in vitro assays. At the microbial level, polyphenols in rhizome extracts downregulate the staphylococcal regulatory genes rsbU and spa, which govern sigma-B stress response and protein A surface adhesin expression respectively, thereby destabilizing biofilm architecture and enhancing susceptibility to antibiotics at 128 µg/mL. No molecular pharmacology data exist specifically for M. grossum; all mechanistic inference is extrapolated from in vitro studies on M. scolopendria.

Scientific Research

No peer-reviewed studies have been conducted specifically on Microsorum grossum (talia) as a medicinal or nutritional ingredient, and no clinical trials of any design exist for either M. grossum or its close relative M. scolopendria. Available evidence consists entirely of in vitro investigations of M. scolopendria extracts, including cell-free antioxidant assays (DPPH, ORAC) and infection models using human dermal fibroblast (HDFa) cells exposed to Staphylococcus aureus and S. epidermidis, as well as RP-HPLC-MS phytochemical profiling studies from Rapa Nui ethnobotanical research programs. These preclinical studies, while generating quantifiable data (e.g., 87.35% ROS reduction, 128 µg/mL biofilm inhibitory concentration), cannot be translated directly to human therapeutic claims due to the absence of pharmacokinetic data, animal toxicology, and dose-escalation studies. The evidence base for M. grossum specifically remains at the level of ethnobotanical observation only, with phytochemical data inferred by taxonomic proximity rather than direct analysis.

Clinical Summary

No clinical trials have been conducted for Microsorum grossum (talia) or its taxonomically related species M. scolopendria in any human population. The Samoan traditional use of the rhizome for coughs and asthma has not been evaluated in observational cohort studies, randomized controlled trials, or even case series in the published biomedical literature. All quantitative outcomes derive from in vitro cell culture and biochemical assay systems, which preclude calculation of human-relevant effect sizes, number-needed-to-treat values, or confidence intervals. Clinical confidence in the efficacy and safety of M. grossum for any indication is therefore very low, and formal evidence-based recommendations cannot be issued pending foundational pharmacological and toxicological research.

Nutritional Profile

Microsorum grossum has not been subjected to proximate nutritional analysis; no data on macronutrient (carbohydrate, protein, lipid), caloric, fiber, mineral, or vitamin content are available in the published literature for either the rhizome or leaf. Phytochemical profiling of the closely related M. scolopendria reveals a phenolic-dominant secondary metabolite profile, with phenolic acids comprising 46–57% relative abundance in rhizome and leaf extracts, flavonoids as the secondary class, and terpenoids enriched particularly in leaf hexane fractions. Key identified compounds in related-species extracts include pyrogallol (9.32%), isoxanthohumol (9.09%), cirsimaritin (8.45%), p-coumaroyl tartaric acid (28%), feruloyl tartaric acid (12.8%), protocatechuic acid 4-O-glucoside (~2%), and kaempferol 3-O-glucuronide (1.41%), all expressed as relative percentage abundance in specific extract fractions rather than as absolute concentrations per gram of dried plant material. Bioavailability data for these compounds specifically from Microsorum preparations are entirely absent from the literature.

Preparation & Dosage

- **Traditional Samoan Preparation**: Rhizome collected, typically dried or used fresh, and prepared as a decoction (boiled water extract) for oral administration to address coughs and asthma; exact volumes and frequencies are not standardized in published ethnobotanical records.
- **Research Extract Forms (Related Species)**: Rhizome acetone extract (RAE) and leaf hydroalcoholic extract (HAE) have been employed in in vitro studies at concentrations up to 128 µg/mL; these laboratory-grade preparations are not commercially available as consumer supplements.
- **No Established Supplemental Dose**: No therapeutic dose range, standardized extract specification, or bioavailability-adjusted dosing protocol has been established for M. grossum or M. scolopendria in any human study.
- **Standardization**: No commercial standardization to any specific marker compound (e.g., pyrogallol, isoxanthohumol, or p-coumaroyl tartaric acid) exists for products derived from either Microsorum species.
- **Timing and Administration**: No clinical guidance on timing, frequency, or route of administration beyond traditional oral decoction use is available in the current literature.

Synergy & Pairings

No pharmacological synergy studies have been conducted for Microsorum grossum, and no evidence-based combination protocols exist. By analogy with the flavonoid and hydroxycinnamic acid constituents identified in related Microsorum species, combinations with other COX-2-modulating polyphenols such as quercetin or curcumin could theoretically produce additive anti-inflammatory effects through complementary pathway engagement, but this hypothesis is untested. Traditional Pacific Island medicine occasionally combines multiple fern and plant preparations in compound remedies for respiratory conditions, but no specific co-ingredient pairings involving talia have been documented in the ethnobotanical literature with sufficient detail to evaluate synergistic potential.

Safety & Interactions

No formal toxicology studies, adverse event reports, or drug interaction data exist for Microsorum grossum, and the limited in vitro data from related M. scolopendria research show no overt cytotoxicity in human dermal fibroblast (HDFa) cells at concentrations up to 128 µg/mL—a finding that cannot be extrapolated to human oral safety without pharmacokinetic and in vivo toxicology investigation. The presence of pyrogallol, a phenolic compound with known nephrotoxic and hemolytic potential at high doses in animal models, warrants caution, as its concentration and oral bioavailability from rhizome preparations have not been characterized. No drug interactions have been identified or studied; however, given the COX-2 inhibitory activity suggested in related-species research, theoretical interactions with NSAIDs, anticoagulants, and corticosteroids should be considered in clinical contexts. Guidance for pregnant or lactating individuals, pediatric populations, or those with hepatic or renal impairment cannot be provided due to a complete absence of relevant safety data, and use of this plant beyond traditional culinary or low-dose traditional medicine contexts is not supported by current evidence.